ImmunArray is a molecular diagnostics company dedicated to the development of novel blood based tests to support the diagnosis and management of complex acute and chronic immune-mediated and neurodegenerative diseases.
Molecular diagnostic company’s research into blood-based diagnosis of traumatic brain injury presented at national conferences
Richmond, Va., July 18, 2016 – Clinical research into ways in which blood-based biomarkers can provide precise and timely diagnosis of traumatic brain injury (TBI) is leading to encouraging results, with some studies resulting in a diagnosis with more than 95 percent sensitivity and specificity.
We are a clinically driven company guided by leadership physician input at each stage of our development. We welcome questions and open discussions, and look forward to continuing to work with our collaborators and partners around the globe.